Keyphrases
Impella
85%
Acute Decompensated Heart Failure
76%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
48%
Cardiogenic Shock
48%
Patients with Heart Failure
30%
Heart Failure
29%
Heart Rate
28%
Tolvaptan
24%
Left Ventricular Assist Device
23%
Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO)
22%
Heart Failure with Preserved Ejection Fraction (HFpEF)
21%
Japan
21%
Short-term Prognosis
21%
Therapeutic Strategies
19%
Systolic Heart Failure
18%
Heart Failure Patients
17%
Type 2 Diabetic Patients
17%
Remote Dielectric Sensing
17%
ECPELLA
17%
Mechanical Circulatory Support
17%
Paracorporeal
16%
Older Men
16%
Impella 5.0
14%
Supportive Therapy
14%
Temporary Mechanical Circulatory Support
14%
Practical Management
14%
Left Ventricle
14%
Confidence Interval
11%
Amiodarone
11%
Canagliflozin
11%
Percutaneous Left Ventricular Assist Device
11%
Type 2 Diabetes Mellitus (T2DM)
11%
Older Women
11%
Dobutamine
11%
Angiopoietin-2
10%
Fluid Level
10%
Arrhythmogenic Right Ventricular Cardiomyopathy
10%
Chronic Myocarditis
10%
Mitral Valve Repair
10%
Transthyretin Amyloidosis
10%
Lung Fluid
10%
Prognostic Impact
10%
Heart Failure Hospitalization
10%
B-type Natriuretic Peptide
9%
Congestive Heart Failure
9%
Left Ventricular Assist Device Support
9%
Tafamidis
9%
Reduced Ejection Fraction
9%
Type 2 Diabetic Mellitus
9%
End-organ Disease
9%
Medicine and Dentistry
Congestive Heart Failure
77%
Cardiogenic Shock
57%
Left Ventricular Assist Device
51%
Assisted Circulation
34%
Extracorporeal Membrane Oxygenation
30%
Hemodynamic
27%
Sodium Glucose Cotransporter 2 Inhibitor
24%
Decompensated Heart Failure
21%
Systolic Heart Failure
18%
Patient with Type 2 Diabetes
17%
Heart Amyloidosis
17%
Tolvaptan
16%
Ventricular Assist Device
15%
Left Ventricle
15%
Heart Failure with Reduced Ejection Fraction
14%
Heart Failure with Preserved Ejection Fraction
14%
Transthyretin
14%
Brain Natriuretic Peptide
12%
Mitral Insufficiency
12%
Myocarditis
11%
Maturity Onset Diabetes of the Young
11%
Ivabradine
10%
Lung Fluid
10%
Arrhythmogenic Right Ventricular Dysplasia
10%
Diabetes Mellitus
10%
Acute Decompensated Heart Failure
9%
Acute Heart Infarction
9%
Ejection Fraction
9%
Combination Therapy
8%
Substitution Therapy
8%
Pulmonary Artery
8%
Dilated Cardiomyopathy
8%
Hemoglobin A1c
8%
Heart Left Ventricle Ejection Fraction
7%
Mitral Valve Repair
7%
Hazard Ratio
7%
Beta Adrenergic Receptor Blocking Agent
7%
Sodium Dihydrogen Phosphate
7%
Patent Foramen Ovale
7%
Takotsubo Cardiomyopathy
7%
Patisiran
7%
Right-to-Left Shunt
7%
Chronic Thromboembolic Pulmonary Hypertension
7%
Heart Ventricle Septum Rupture
7%
Mitral Annulus
7%
Angioplasty
7%
Surgery
7%
Acute Coronary Syndrome
7%
Pulmonary Artery Occlusion Pressure
7%
Artery
7%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Sodium Glucose Cotransporter 2 Inhibitor
38%
Acute Heart Failure
25%
Tolvaptan
18%
Non Insulin Dependent Diabetes Mellitus
18%
Heart Amyloidosis
14%
Transthyretin
14%
Cardiogenic Shock
14%
Dobutamine
12%
Canagliflozin
11%
Brain Natriuretic Peptide
11%
Heart Failure with Reduced Ejection Fraction
11%
Amiodarone
9%
Tafamidis
8%
Diabetes Mellitus
8%
Hemoglobin A1c
8%
Loop Diuretic Agent
7%
Heart Failure with Preserved Ejection Fraction
7%
Influenza
7%
Takotsubo Cardiomyopathy
7%
Patisiran
7%
Mitral Valve Regurgitation
7%
Ivabradine
7%
Becker Muscular Dystrophy
7%
Beta Adrenergic Receptor Blocking Agent
7%
Cotransporter
7%
Hyponatremia
7%
Myocarditis
7%
Clotting Time
7%
Heart Right Ventricle Dysplasia
7%
Combination Therapy
6%
Hypotension
6%
Lung Congestion
5%